# **Special Issue**

# State of the Art Papers from the XXXI IACRLD Symposium

# Message from the Guest Editors

The XXXI Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, IACRLRD, was held in Bologna, Italy, from August 31 to September 2, 2023, with the participation of many leaders in the field of hematological malignancies. The symposium is always an outstanding event of this association, taking place at various sites worldwide every two years. The recent COVID-19 pandemic highlighted the importance of networking between researchers in all fields of medicine to promote the sharing of knowledge on the virus, inflammation, and hematological malignancies. Furthermore, the availability of genome sequences in humans and animal species opens up new avenues for comparative research and novel therapeutic approaches. In addition to conventional treatment strategies, such as chemotherapeutic drugs and radiotherapy, which have now become completely personalized, immunotherapy has become an efficient strategy for treating cancer. This Special Issue will present research papers, reviews, particularly interesting case reports, and state-of-the-art papers from IACRLRD.

#### **Guest Editors**

Prof. Dr. Ali Bazarbachi

Dr. Claudio Cerchione

Dr. Giovanni Martinelli

Prof. Dr. Giuseppe Saglio

# Deadline for manuscript submissions

closed (1 December 2024)



# Hematology Reports

an Open Access Journal by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



## mdpi.com/si/192121

Hematology Reports Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 hematolrep@mdpi.com

mdpi.com/journal/ hematolrep





# Hematology Reports

an Open Access Journal by MDPI

Impact Factor 1.2 CiteScore 1.4 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Hematology Reports (ISSN 2038-8330) is an international open access journal on all aspects of prevention, diagnosis and management of disorders of the blood, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology and controlled trials.

## Editor-in-Chief

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

### **Author Benefits**

# **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

# **High Visibility:**

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 26.9 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

